{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T09:42:29Z","timestamp":1771234949104,"version":"3.50.1"},"reference-count":24,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100017624","name":"Achaogen, Inc.","doi-asserted-by":"crossref","award":["A16040-1490-EF-M"],"award-info":[{"award-number":["A16040-1490-EF-M"]}],"id":[{"id":"10.13039\/100017624","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:p>\n            Plazomicin is a novel aminoglycoside with potent\n            <jats:italic>in vitro<\/jats:italic>\n            activity against multidrug- and carbapenem-resistant\n            <jats:named-content content-type=\"genus-species\">Enterobacteriaceae<\/jats:named-content>\n            . The objective of this study was to assess the efficacy of plazomicin exposure, alone and in combination with meropenem or tigecycline, against\n            <jats:named-content content-type=\"genus-species\">Enterobacteriaceae<\/jats:named-content>\n            in the immunocompetent murine septicemia model.\n          <\/jats:p>","DOI":"10.1128\/aac.01074-18","type":"journal-article","created":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T09:16:33Z","timestamp":1527844593000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":24,"title":["<i>In Vivo<\/i>\n            Efficacy of Plazomicin Alone or in Combination with Meropenem or Tigecycline against Enterobacteriaceae Isolates Exhibiting Various Resistance Mechanisms in an Immunocompetent Murine Septicemia Model"],"prefix":"10.1128","volume":"62","author":[{"given":"Kamilia","family":"Abdelraouf","sequence":"first","affiliation":[{"name":"Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aryun","family":"Kim","sequence":"additional","affiliation":[{"name":"Achaogen, Inc., South San Francisco, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin M.","family":"Krause","sequence":"additional","affiliation":[{"name":"Achaogen, Inc., South San Francisco, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David P.","family":"Nicolau","sequence":"additional","affiliation":[{"name":"Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA"},{"name":"Division of Infectious Diseases, Hartford Hospital, Hartford, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir202"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofv050"},{"key":"e_1_3_2_4_2","volume-title":"Antibiotic resistance threats in the United States","author":"Centers for Disease Control and Prevention","year":"2013","unstructured":"Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States. Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, GA."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02349-16"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1586\/eri.12.25"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02744-13"},{"key":"e_1_3_2_8_2","volume-title":"Abstr IDWeek 2017, San Diego, CA, USA","author":"McKinnell JA","year":"2017","unstructured":"McKinnell JA, Connolly LE, Pushkin R, Jubb AM, O'Keeffe B, Serio AW, Smith A, Gall J, Riddle V, Krause KM, Pogue JM. 2017. Improved outcomes with plazomicin (PLZ) compared with colistin (CST) in patients with bloodstream infections (BSI) caused by carbapenem-resistant enterobacteriaceae (CRE): results from the CARE study, abstr 1853. Abstr IDWeek 2017, San Diego, CA, USA. Infectious Diseases Society of America, Arlington, VA."},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","unstructured":"Abdelraouf K Kim A Krause KM Nicolau DP. 2017. Assessment of the in vivo efficacy of plazomicin (PLZ) alone or in combination with meropenem (MEM) or tigecycline (TGC) against Enterobacteriaceae (EB) isolates exhibiting various resistance mechanisms in an immunocompetent (I+) murine septicemia model abstr 1506. IDWeek 2017 San Diego CA USA. Infectious Diseases Society of America Arlington VA.","DOI":"10.1093\/ofid\/ofx163.1202"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02429-13"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01165-15"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-010-2105-0"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12341"},{"key":"e_1_3_2_14_2","volume-title":"CLSI supplement M100","author":"Clinical and Laboratory Standards Institute","year":"2017","unstructured":"Clinical and Laboratory Standards Institute. 2017. Performance standards for antimicrobial susceptibility testing, 27th ed. CLSI supplement M100. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"27"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01173-15"},{"key":"e_1_3_2_16_2","volume-title":"Abstr IDWeek 2017, San Diego, CA, USA","author":"Castanheira M","year":"2017","unstructured":"Castanheira M, Deshpande L, Hubler C, Mendes R, Serio A, Krause K, Flamm R. 2017. Activity of plazomicin against Enterobacteriaceae isolates collected in the United States including isolates carrying aminoglycoside-modifying enzymes detected by whole genome sequencing, abstr 1235. Abstr IDWeek 2017, San Diego, CA, USA. Infectious Diseases Society of America, Arlington, VA."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02190-12"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis001"},{"key":"e_1_3_2_19_2","volume-title":"Non-compartmental pharmacokinetic analysis for study ACHN-490-006, a randomized, double-blind, placebo and positive-controlled, crossover study to evaluate the effect of intravenous ACHN-490 injection on the QT\/QTc interval in healthy volunteers","author":"Wart SV","year":"2012","unstructured":"Wart SV, Rubino CM, Reynolds DK. 2012. Non-compartmental pharmacokinetic analysis for study ACHN-490-006, a randomized, double-blind, placebo and positive-controlled, crossover study to evaluate the effect of intravenous ACHN-490 injection on the QT\/QTc interval in healthy volunteers. Institute for Clinical Pharmacodynamics, Inc, Latham, NY."},{"key":"e_1_3_2_20_2","volume-title":"Assessment of protein binding of ACHN-490 in plasma","author":"Wu S","year":"2017","unstructured":"Wu S. 2017. Study report. Assessment of protein binding of ACHN-490 in plasma. Quintara Discovery, Hayward, CA."},{"key":"e_1_3_2_21_2","volume-title":"Abstr ASM Microbe 2017, New Orleans, LA, USA","author":"Seroogy J","year":"2017","unstructured":"Seroogy J, Choi T, Gall J, Van Wart S. 2017. Pharmacokinetics (PK) of plazomicin in healthy adults, abstr 206. Abstr ASM Microbe 2017, New Orleans, LA, USA. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00794-15"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00647-08"},{"key":"e_1_3_2_24_2","volume-title":"Tygacil\u00ae (tigecycline) for injection for intravenous use","author":"Wyeth Pharmaceuticals Inc","year":"2005","unstructured":"Wyeth Pharmaceuticals Inc. 2005. Tygacil\u00ae (tigecycline) for injection for intravenous use. Wyeth Pharmaceuticals Inc, Philadelphia, PA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021821s021lbl.pdf."},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(96)00205-8"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01074-18","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01074-18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:18:58Z","timestamp":1645478338000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01074-18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["10.1128\/AAC.01074-18"],"URL":"https:\/\/doi.org\/10.1128\/aac.01074-18","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"2018-05-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01074-18"}}